166 related articles for article (PubMed ID: 36706588)
21. Genomic and Epigenomic Profile of Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMPs) Revealed Similarities and Differences with Leiomyomas and Leiomyosarcomas.
Conconi D; Redaelli S; Lissoni AA; Cilibrasi C; Perego P; Gautiero E; Sala E; Paderno M; Dalprà L; Landoni F; Lavitrano M; Roversi G; Bentivegna A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557274
[TBL] [Abstract][Full Text] [Related]
22. Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma.
Montgomery EA; Shuster DD; Burkart AL; Esteban JM; Sgrignoli A; Elwood L; Vaughn DJ; Griffin CA; Epstein JI
Am J Surg Pathol; 2006 Dec; 30(12):1502-12. PubMed ID: 17122505
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.
Ünver NU; Acikalin MF; Öner Ü; Ciftci E; Ozalp SS; Colak E
Arch Gynecol Obstet; 2011 Aug; 284(2):483-90. PubMed ID: 20878171
[TBL] [Abstract][Full Text] [Related]
24. Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia.
Oliva E
Mod Pathol; 2016 Jan; 29 Suppl 1():S104-20. PubMed ID: 26715170
[TBL] [Abstract][Full Text] [Related]
25. Uterine Inflammatory Myofibroblastic Tumor Showing an Atypical ALK Signal Pattern by FISH and DES-ALK Fusion by RNA Sequencing: A Case Report.
Zarei S; Abdul-Karim FW; Chase DM; Astbury C; Policarpio-Nicolas MLC
Int J Gynecol Pathol; 2020 Mar; 39(2):152-156. PubMed ID: 30741845
[TBL] [Abstract][Full Text] [Related]
26. Myxoid Leiomyosarcoma of the Uterus: A Clinicopathologic Analysis of 30 Cases and Review of the Literature With Reappraisal of Its Distinction From Other Uterine Myxoid Mesenchymal Neoplasms.
Parra-Herran C; Schoolmeester JK; Yuan L; Dal Cin P; Fletcher CD; Quade BJ; Nucci MR
Am J Surg Pathol; 2016 Mar; 40(3):285-301. PubMed ID: 26866354
[TBL] [Abstract][Full Text] [Related]
27. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
[TBL] [Abstract][Full Text] [Related]
28. Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report.
Takahashi A; Kurosawa M; Uemura M; Kitazawa J; Hayashi Y
J Int Med Res; 2018 Aug; 46(8):3498-3503. PubMed ID: 29900760
[TBL] [Abstract][Full Text] [Related]
29. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases.
Ip PP; Cheung AN; Clement PB
Am J Surg Pathol; 2009 Jul; 33(7):992-1005. PubMed ID: 19417585
[TBL] [Abstract][Full Text] [Related]
30. Anaplastic lymphoma kinase inhibitor therapy in the treatment of inflammatory myofibroblastic tumors in pediatric patients: Case reports and literature review.
Craig E; Wiltsie LM; Beaupin LK; Baig A; Kozielski R; Rothstein DH; Li V; Twist CJ; Barth M
J Pediatr Surg; 2021 Dec; 56(12):2364-2371. PubMed ID: 33676744
[TBL] [Abstract][Full Text] [Related]
31. STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.
Subbiah V; McMahon C; Patel S; Zinner R; Silva EG; Elvin JA; Subbiah IM; Ohaji C; Ganeshan DM; Anand D; Levenback CF; Berry J; Brennan T; Chmielecki J; Chalmers ZR; Mayfield J; Miller VA; Stephens PJ; Ross JS; Ali SM
J Hematol Oncol; 2015 Jun; 8():66. PubMed ID: 26062823
[TBL] [Abstract][Full Text] [Related]
32. Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblasts.
Qiu X; Montgomery E; Sun B
Hum Pathol; 2008 Jun; 39(6):846-56. PubMed ID: 18400254
[TBL] [Abstract][Full Text] [Related]
33. Biomarker resolution of uterine smooth muscle tumor necrosis as benign vs malignant.
Yang EJ; Mutter GL
Mod Pathol; 2015 Jun; 28(6):830-5. PubMed ID: 25698060
[TBL] [Abstract][Full Text] [Related]
34. Rare presentation of inflammatory myofibroblastic tumor on a digit.
West CE; Workman A; Moody T; Hosler GA
J Cutan Pathol; 2021 Jul; 48(7):965-968. PubMed ID: 33754372
[TBL] [Abstract][Full Text] [Related]
35. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
[TBL] [Abstract][Full Text] [Related]
36. Inflammatory myofibroblastic tumor of bone harboring an ALK gene amplification.
Wang K; Guo R; Siegal GP; Wei S
Pathol Res Pract; 2019 Sep; 215(9):152535. PubMed ID: 31326196
[TBL] [Abstract][Full Text] [Related]
37. Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions.
Croce S; Ribeiro A; Brulard C; Noel JC; Amant F; Stoeckle E; Devouassoux-Shisheborah M; Floquet A; Arnould L; Guyon F; Mishellany F; Garbay D; Cuppens T; Zikan M; Leroux A; Frouin E; Duvillard P; Terrier P; Farre I; Valo I; MacGrogan GM; Chibon F
Mod Pathol; 2015 Jul; 28(7):1001-10. PubMed ID: 25932961
[TBL] [Abstract][Full Text] [Related]
38. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.
Chang JC; Zhang L; Drilon AE; Chi P; Alaggio R; Borsu L; Benayed R; Travis WD; Ladanyi M; Antonescu CR
J Thorac Oncol; 2019 May; 14(5):825-834. PubMed ID: 30550870
[TBL] [Abstract][Full Text] [Related]
39. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases.
Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R
Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968
[TBL] [Abstract][Full Text] [Related]
40. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]